Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study

Annals of the Rheumatic Diseases

Volumn 64, Issue 11, 2005, Pages 1568-1575

  Marzo Ortega, H ^b   McGonagle, D ^b,c   Jarrett, S ^b   Haugeberg, G ^d   Hensor, E ^b   O'Connor, P ^b   Tan, A L ^b   Conaghan, P G ^b   Greenstein, A ^b   Emery, P ^a,b  

^a Department of Rheumatology   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c Department of Rheumatology   (United Kingdom)

^d Vest Agder Central Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTHESITIS; FEMALE; HERPES ZOSTER; HUMAN; IRITIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; SORE THROAT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BONE DENSITY; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUMBAR VERTEBRAE; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; SACROILIAC JOINT; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22144494850     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.022582     Document Type: Article

References (29)

1. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural course of disease in ankylosing spondylitis. Arthritis Rheum 1983;26:186-90.
2. Ward MM. Quality of life in patients with ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
3. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
5. German JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl J Med 2002;346:1349-56.
6. Moreland LW. Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. J Rheumatol 1996;23(suppl 44):78-83.
7. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000;19:114-17.
8. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Sabana AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000;29:160-2.
9. Elliolt MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
10. Maini R, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
11. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
12. Marzo-Ortega H, Braun J, Maksymowych W, O'Connor P, Lambert R, Inman R et al. Interreader agreement in the assessement of MRI of the sacroiliac joints in spondyloarthropathy [abstract]. Arthritis Rheum 2002;46(suppl):S428.
13. Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roque M, Canosa M, et al. Significant loss of bone mass in patients with early ankylosing spondylitis: a follow up study. Arthritis Rheum 1999;42:2319-24.
14. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
15. Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis. The Bath ankylosing sponydylitis disease activity index. J Rheumatol 1994;24:225-9.
16. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
17. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.
18. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1878-86.
19. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, for the ASAS Working Group, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
20. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. A clinical and magnetic resonance study. Arthritis Rheum 2001;44:2112-17.
21. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys E. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
22. Brandt J, Haibel H, Comely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
23. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statistics 1979;6:65-70.
24. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. An open, observational, extension study of a three-month randomized placebo controlled trial. Arthritis Rheum 2003;48:2224-33.
25. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 2003;48:1015-23.
26. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
27. Braun J, Baralakios X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with anlwlosing spondylitis before and after successful treatment with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
28. Marzo-Ortega H, McGonagle D, Haugeberg G, Green MJ, Stewart SP, Emery P. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003;62:1020-1.
29. Marzo-Ortega H, McGonagle D, Haugeberg G, Astin P, Conaghan PG, Emery P. Significant loss of bone mass occurs early in inflammatory back pain in undifferentiated spondyloarthropathy [abstract]. Rheumatology (Oxford) 2002;41(suppl):S311.